CL2007002163A1 - Compuestos derivados de 2-fenilindol, antagonistas del receptor de prostaglandina d2; composicion farmaceutica; y uso para tratar enfermedades alergicas tales como asma bronquial y rinitis alergica, broncoconstriccion, epoc, accidente cerebrovascular - Google Patents
Compuestos derivados de 2-fenilindol, antagonistas del receptor de prostaglandina d2; composicion farmaceutica; y uso para tratar enfermedades alergicas tales como asma bronquial y rinitis alergica, broncoconstriccion, epoc, accidente cerebrovascularInfo
- Publication number
- CL2007002163A1 CL2007002163A1 CL200702163A CL2007002163A CL2007002163A1 CL 2007002163 A1 CL2007002163 A1 CL 2007002163A1 CL 200702163 A CL200702163 A CL 200702163A CL 2007002163 A CL2007002163 A CL 2007002163A CL 2007002163 A1 CL2007002163 A1 CL 2007002163A1
- Authority
- CL
- Chile
- Prior art keywords
- prostaglandina
- broncoconstriction
- phenylindol
- copd
- antagonists
- Prior art date
Links
- KLLLJCACIRKBDT-UHFFFAOYSA-N 2-phenyl-1H-indole Chemical compound N1C2=CC=CC=C2C=C1C1=CC=CC=C1 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 title 1
- 206010008190 Cerebrovascular accident Diseases 0.000 title 1
- 206010039085 Rhinitis allergic Diseases 0.000 title 1
- 208000006011 Stroke Diseases 0.000 title 1
- 230000000172 allergic effect Effects 0.000 title 1
- 201000010105 allergic rhinitis Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000006673 asthma Diseases 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000026106 cerebrovascular disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82030106P | 2006-07-25 | 2006-07-25 | |
| US82030206P | 2006-07-25 | 2006-07-25 | |
| US82029906P | 2006-07-25 | 2006-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007002163A1 true CL2007002163A1 (es) | 2008-02-08 |
Family
ID=38610820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL200702163A CL2007002163A1 (es) | 2006-07-25 | 2007-07-24 | Compuestos derivados de 2-fenilindol, antagonistas del receptor de prostaglandina d2; composicion farmaceutica; y uso para tratar enfermedades alergicas tales como asma bronquial y rinitis alergica, broncoconstriccion, epoc, accidente cerebrovascular |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20090176804A1 (enExample) |
| EP (1) | EP2066628B1 (enExample) |
| JP (1) | JP2009544721A (enExample) |
| KR (1) | KR20090039735A (enExample) |
| AR (1) | AR062051A1 (enExample) |
| AT (1) | ATE485270T1 (enExample) |
| AU (1) | AU2007276885A1 (enExample) |
| BR (1) | BRPI0714554A2 (enExample) |
| CA (1) | CA2659055A1 (enExample) |
| CL (1) | CL2007002163A1 (enExample) |
| CO (1) | CO6190511A2 (enExample) |
| CR (1) | CR10577A (enExample) |
| DE (1) | DE602007010010D1 (enExample) |
| DK (1) | DK2066628T3 (enExample) |
| EC (1) | ECSP099087A (enExample) |
| GT (1) | GT200900016A (enExample) |
| IL (1) | IL196587A0 (enExample) |
| MA (1) | MA30643B1 (enExample) |
| MX (1) | MX2009000830A (enExample) |
| NO (1) | NO20090862L (enExample) |
| PE (1) | PE20080549A1 (enExample) |
| PT (1) | PT2066628E (enExample) |
| TN (1) | TNSN08515A1 (enExample) |
| TW (1) | TW200821286A (enExample) |
| WO (1) | WO2008014186A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2009072576A1 (ja) * | 2007-12-04 | 2011-04-28 | サッポロビール株式会社 | 骨形成促進剤 |
| MX2011005120A (es) * | 2008-11-17 | 2011-05-30 | Hoffmann La Roche | Acidos naftilaceticos. |
| SI2558447T1 (sl) | 2010-03-22 | 2015-01-30 | Actelion Pharmaceuticals Ltd. | Derivati 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-karbazola in njihova uporaba kot modulatorji prostaglandinskega receptorja d2 |
| EP2697223B1 (en) | 2011-04-14 | 2016-07-13 | Actelion Pharmaceuticals Ltd. | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| US9797903B2 (en) | 2012-10-24 | 2017-10-24 | Winthrop-University Hospital | Non-invasive biomarker to identify subject at risk of preterm delivery |
| JP2015089886A (ja) * | 2013-11-06 | 2015-05-11 | 国立大学法人名古屋大学 | 嵩高い置換基を有する化合物を用いた植物成長調整剤 |
| HRP20181555T1 (hr) | 2014-03-17 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Derivati azaindol-octene kiseline i njihova uporaba kao modulatora receptora prostaglandina d2 |
| EP3119780B1 (en) | 2014-03-18 | 2018-08-29 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| EA035752B1 (ru) | 2015-09-15 | 2020-08-05 | Идорсиа Фармасьютиклз Лтд | КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-2-(8-((5-ХЛОРПИРИМИДИН-2-ИЛ)(МЕТИЛ)-АМИНО)-2-ФТОР-6,7,8,9-ТЕТРАГИДРО-5Н-ПИРИДО[3,2-b]ИНДОЛ-5-ИЛ)УКСУСНОЙ КИСЛОТЫ И СОДЕРЖАЩИЕ ЕЁ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ |
| US20200264188A1 (en) | 2017-09-13 | 2020-08-20 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
| WO2019166628A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US12168653B2 (en) | 2018-03-02 | 2024-12-17 | Inflazome Limited | Sulfonamide derivates as NLRP3 inhibitors |
| EP3759102A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| WO2019166632A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| JP7455762B2 (ja) * | 2018-05-09 | 2024-03-26 | グルソックス・バイオテック・アーベー | 選択的なＮｏｘ阻害活性を有する新規のスルホンアミド誘導体 |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN111333516B (zh) * | 2020-04-14 | 2022-09-06 | 国药集团化学试剂有限公司 | 一种2-氯-5-溴硝基苯的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000016A (es) * | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
-
2007
- 2007-07-20 WO PCT/US2007/073945 patent/WO2008014186A1/en not_active Ceased
- 2007-07-20 AU AU2007276885A patent/AU2007276885A1/en not_active Abandoned
- 2007-07-20 BR BRPI0714554-3A patent/BRPI0714554A2/pt not_active IP Right Cessation
- 2007-07-20 KR KR1020097001687A patent/KR20090039735A/ko not_active Abandoned
- 2007-07-20 PT PT07799729T patent/PT2066628E/pt unknown
- 2007-07-20 MX MX2009000830A patent/MX2009000830A/es active IP Right Grant
- 2007-07-20 DE DE602007010010T patent/DE602007010010D1/de active Active
- 2007-07-20 JP JP2009521914A patent/JP2009544721A/ja not_active Abandoned
- 2007-07-20 CA CA002659055A patent/CA2659055A1/en not_active Abandoned
- 2007-07-20 AT AT07799729T patent/ATE485270T1/de active
- 2007-07-20 EP EP07799729A patent/EP2066628B1/en active Active
- 2007-07-20 DK DK07799729.4T patent/DK2066628T3/da active
- 2007-07-23 PE PE2007000951A patent/PE20080549A1/es not_active Application Discontinuation
- 2007-07-24 AR ARP070103291A patent/AR062051A1/es not_active Application Discontinuation
- 2007-07-24 CL CL200702163A patent/CL2007002163A1/es unknown
- 2007-07-25 TW TW096127005A patent/TW200821286A/zh unknown
-
2008
- 2008-12-12 TN TNP2008000515A patent/TNSN08515A1/en unknown
-
2009
- 2009-01-15 CO CO09002745A patent/CO6190511A2/es not_active Application Discontinuation
- 2009-01-19 IL IL196587A patent/IL196587A0/en unknown
- 2009-01-21 CR CR10577A patent/CR10577A/es not_active Application Discontinuation
- 2009-01-22 US US12/357,725 patent/US20090176804A1/en not_active Abandoned
- 2009-01-23 GT GT200900016A patent/GT200900016A/es unknown
- 2009-01-23 EC EC2009009087A patent/ECSP099087A/es unknown
- 2009-02-13 MA MA31635A patent/MA30643B1/fr unknown
- 2009-02-24 NO NO20090862A patent/NO20090862L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2066628A1 (en) | 2009-06-10 |
| KR20090039735A (ko) | 2009-04-22 |
| CO6190511A2 (es) | 2010-08-19 |
| TNSN08515A1 (en) | 2010-04-14 |
| WO2008014186A1 (en) | 2008-01-31 |
| DE602007010010D1 (de) | 2010-12-02 |
| EP2066628B1 (en) | 2010-10-20 |
| PT2066628E (pt) | 2010-12-31 |
| IL196587A0 (en) | 2009-11-18 |
| CA2659055A1 (en) | 2008-01-31 |
| GT200900016A (es) | 2010-10-13 |
| AU2007276885A1 (en) | 2008-01-31 |
| TW200821286A (en) | 2008-05-16 |
| US20090176804A1 (en) | 2009-07-09 |
| AR062051A1 (es) | 2008-08-10 |
| BRPI0714554A2 (pt) | 2013-05-07 |
| MA30643B1 (fr) | 2009-08-03 |
| ATE485270T1 (de) | 2010-11-15 |
| DK2066628T3 (da) | 2011-02-07 |
| NO20090862L (no) | 2009-02-24 |
| ECSP099087A (es) | 2009-02-27 |
| JP2009544721A (ja) | 2009-12-17 |
| PE20080549A1 (es) | 2008-06-20 |
| CR10577A (es) | 2009-03-20 |
| MX2009000830A (es) | 2009-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2007002163A1 (es) | Compuestos derivados de 2-fenilindol, antagonistas del receptor de prostaglandina d2; composicion farmaceutica; y uso para tratar enfermedades alergicas tales como asma bronquial y rinitis alergica, broncoconstriccion, epoc, accidente cerebrovascular | |
| CL2008000307A1 (es) | Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc. | |
| IL212605A0 (en) | Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd | |
| UY30917A1 (es) | Moduladores 2-aminopiridina del receptor histamina h | |
| CL2007003804A1 (es) | Compuestos derivados de indazol; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar condiciones inflamatorias, tales como asma, epoc. | |
| CL2008000911A1 (es) | Compuestos derivados de pirimidina, inhibidores de prostaglandina d2; composicion farmaceutica; y uso para tratar un trastorno alergico o inflamatorio tal como rinitis alergica, asma y epoc. | |
| CL2007003765A1 (es) | Compuestos derivados de 2-oxo-4-hidroxi-benzotiazol; procesode preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, bronquitis, asma y bronquiectasias. | |
| CL2008003694A1 (es) | Compuestos derivados de heterociclo-2-carboxamida sustituida; composicion farmaceutica; combinacion farmaceutica; y su uso como inhibidores de dipeptidil peptidasa iv (dpp-iv) en el tratamiento del asma, epoc y rinitis alergica. | |
| MX2012006964A (es) | Nuevos antagonistas del receptor ccr2 y usos de los mismos. | |
| CL2007002274A1 (es) | Compuestos derivados del acido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acetico; composicion farmaceutica; y uso para la prevencion y/o tratamiento de enfermedades alergicas e inmunes, tales como asma, epoc y rinitis entre otras. | |
| CL2008003097A1 (es) | Compuestos derivados de 2-il-piperazin-1-il-pirimidin-4-il-tieno[3,2-d]aminas sustituidas, composicion farmaceutica y su uso como inhibidores de pde4 para el tratamiento de trastornos gastrointestinales, respiratorios y del sistema nervioso periferico o central, tales como epoc, sinusitis cronica, asma, depresion y esquizofrenia. | |
| CL2012001807A1 (es) | Compuestos derivados de naftiridina, inhibidores de syk quinasa; compuestos intermediarios, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades tales como rinitis alergica, asma, epoc, lupus eritematoso, urticaria/angioedema, entre otros. | |
| IL214572A (en) | Annals of 9 - Alkylaryl - 9h - Furin - 6 - Converted Illamine, a Pharmaceutical Composition Containing Them and These Compounds That Are a Toll-like Colton Antagonist for the Treatment of Disease | |
| SMT201600164B (it) | Nuove n-acil-5, 6, 7, ( 8-s0stituito )-tetraidro-[1, 2, 4]triazolo[4, 3-a]pirazine chirali come antagonisti selettivi del recettore nk-3, composizione farmaceutica, e metodi per l'uso in disturbi mediati dal recettore nk-3 | |
| CL2014000296A1 (es) | Compuestos derivados de sulfoxidos de 2-(piperidin-1-il)-dihidrotieno[3,2-d]pirimidina; metodo de preparacion; compuestos intermediarios; y uso para tratar enfermedades inflamatorias o alergicas tales como epoc y asma. | |
| CL2007001481A1 (es) | Compuestos derivados de pirrolidina sustituidas, inhibidores de proteasa activadora de canal; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como fibrosis quistica, bronquitis cronica, epoc, asma e infecciones de las vias r | |
| CL2008001215A1 (es) | Compuestos derivados de heterociclos nitrogenados condensados; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, dislipidemia, obesidad y alzheimer. | |
| CR20130643A (es) | Combinación que comprende umeclidinio y un corticosteroide | |
| CL2008000690A1 (es) | Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras. | |
| CL2014003031A1 (es) | Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras. | |
| CL2008000474A1 (es) | Compuestos derivados de azonia-biciclo-[2.2.2]octano, moduladores del receptor m3; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, asma, sindrome del intestino irritable, entre otras. | |
| CL2008000289A1 (es) | Compuestos derivados de pirano[2,3-b]piridina, moduladores del receptor cannabinoide-1; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como psicosis, enfermedad de alzheimer, migrana, enfermedad de parkinson, asma y obesida | |
| CL2007003720A1 (es) | Compuestos derivados de espiro-piperidina, moduladores del receptor de vasopresina v1a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermemdades tales como dismenorrea, hipertension, ansiedad y trastornos depresivos. | |
| CL2007003103A1 (es) | Compuestos derivados de piperidil-propano-tioles, moduladores de la actividad del receptor de quimioquina; composicion farmaceutica; y uso para el tratamiento de asma y enfermedades alergicas, epoc, infecciones por microbios patogenos, artritis reuma | |
| UY31635A1 (es) | Farmacóforos duales-antagonistas muscarínicos de pde4 |